Telix Pharmaceuticals Limited

ASX (AUD): Telix Pharmaceuticals Limited (TLX)

Last Price

19.94

Today's Change

+0.01 (0.05%)

Day's Change

19.79 - 20.54

Trading Volume

2,386,985

Overview

Market Cap

6 Billion

Shares Outstanding

334 Million

Avg Volume

1,312,096

Avg Price (50 Days)

16.99

Avg Price (200 Days)

12.53

PE Ratio

997.00

EPS

0.02

Earnings Announcement

21-Aug-2024

Previous Close

19.93

Open

20.10

Day's Range

19.79 - 20.54

Year Range

8.2 - 20.54

Trading Volume

2,386,985

Price Change Highlight

1 Day Change

0.05%

5 Day Change

11.40%

1 Month Change

20.05%

3 Month Change

54.45%

6 Month Change

86.01%

Ytd Change

97.82%

1 Year Change

69.99%

3 Year Change

281.26%

5 Year Change

1094.01%

10 Year Change

2489.61%

Max Change

2489.61%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment